Alzheimer drug design based on the amyloid hypothesisMUNOZ-TORRERO, Diego; CAMPS, Pelayo.Current pharmaceutical design. 2006, Vol 12, Num 33, issn 1381-6128, 129 p.Serial Issue

Vaccine development for Alzheimer's diseaseDASILVA, Kevin A; AUBERT, Isabelle; MCLAURIN, Joanne et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4283-4293, issn 1381-6128, 11 p.Article

Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease : Progress and problemsNGUYEN, Jeffrey-Tri; YAMANI, Abdellah; KISO, Yoshiaki et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4295-4312, issn 1381-6128, 18 p.Article

Gamma-secretase as a pharmacological target in Alzheimer disease research : When, why and how?ZIANI-CHERIF, Chewki; MOSTEFA-KARA, Bachir; BRIXI-GORMAT, Fatima Z et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4313-4335, issn 1381-6128, 23 p.Article

Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitorsCASTRO, Ana; MARTINEZ, Ana.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4377-4387, issn 1381-6128, 11 p.Article

Molecular and biochemical features in Alzheimer's diseasePALLAS, Mercè; CAMINS, Antoni.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4389-4408, issn 1381-6128, 20 p.Article

Selective modulation of Aβ42 production in Alzheimer's disease : Non-steroidal anti-inflammatory drugs and beyondLEUCHTENBERGER, Stefanie; BEHER, Dirk; WEGGEN, Sascha et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4337-4355, issn 1381-6128, 19 p.Article

The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of β-amyloid fibrils (fAβ), as well as destabilize preformed fAβONO, Kenjiro; NAIKI, Hironobu; YAMADA, Masahito et al.Current pharmaceutical design. 2006, Vol 12, Num 33, pp 4357-4375, issn 1381-6128, 19 p.Article